Article

jdsupra.com on 2024-04-02 21:36

Celltrion Submits aBLA for CT-P39, Proposed Interchangeable Biosimilar of Xolair® (omalizumab)

On March 10, 2024, Celltrion announced in a press release that it submitted an abbreviated Biologics License Application (aBLA) for FDA approval of ...

Related news

Celltrion Submits an aBLA for Actemra® (tocilizumab) Proposed Biosimilar CT-P47 jdsupra.com
FDA Accepts Mylan aBLA or Pegfilgrastim Biosimilar jdsupra.com
FDA Approves Lantus® Interchangeable Biosimilar jdsupra.com
FDA Approves Another Interchangeable Biosimilar jdsupra.com
FDA Accepts Coherus’s aBLA for Neulasta® Biosimilar jdsupra.com
FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilar jdsupra.com
Celltrion Submits BLA for Omalizumab Biosimilar jdsupra.com
United States
FDA Approves Another Interchangeable Biosimilar Drug jdsupra.com
Lupin Announces FDA Acceptance of aBLA for Pegfilgrastim Biosimilar jdsupra.com
India , Mumbai , Manzhouli
AbbVie Submits Citizen Petition on Interchangeable Biosimilars jdsupra.com
Breaking News – FDA Approves First Interchangeable Biosimilar Insulin Product jdsupra.com
FDA Accepts aBLA for Mylan-Biocon’s Proposed Herceptin® Biosimilar jdsupra.com
FDA accepts Celltrion/Teva BLA for biosimilar of Rituxan®jdsupra.com
Celltrion USA Announces Submission of BLA for Subcutaneous Infliximab Biosimilar jdsupra.com
Biosimilar Market Updates: Samsung Biologics, Celltrion, and Alvotech jdsupra.com
Yangtze River , China , Incheon , South Korea
Celltrion Files IND with FDA for Adalimumab Biosimilar jdsupra.com
United States , South Korea
FDA Accepts Bio-Thera’s aBLA for Proposed Stelara® (Ustekinumab) Interchangeable BAT2206 jdsupra.com
FDA Accepts Samsung Bioepis’ aBLA for Herceptin® Biosimilar jdsupra.com
FDA Approves First Interchangeable Biosimilar Insulin Product - Update jdsupra.com
FDA Issues Guidance for Applicants Seeking Biosimilar/Interchangeable Approval jdsupra.com